首站-论文投稿智能助手
典型文献
Detection of SARS-CoV-2 Eta VOI among international travelers using COVIDSeq-NGS
文献摘要:
Rationale: SARS-CoV-2 has been identified as a highly infective and contagious viral infection. The SARS-CoV-2 pandemic has been spread worldwide and affected more than 210 countries. Globally, the fast spread of novel SARS-CoV-2 variants has been mostly attributed to international travel. Patient concerns: We are reporting the genomic evidence of SARS-CoV-2 Eta VOI among two international travelers. Both travelers were males from Nigeria aged 24 and 34 years and both were asymptomatic. Diagnosis: The nasopharyngeal swab samples were in both travelers positive by real-time RT-PCR followed by COVIDSeq-NGS. Interventions: Paracetamol 3 times daily for 5 days. Outcomes: Patient recovered completely within 10 days and discharged after 14 days of quarantine duration. Lessons: This report highlights genomic variation of SARS-CoV-2 among the travelers. For managing the present health crisis, molecular identification of viral variants present in different geographical locations will be very helpful.
文献关键词:
作者姓名:
Mati Ur Rehman;Rooh Ullah;Narmeen Arshad;Muhammad Ammad;Qurat Ul Ain;Anam Razzak;Muhammad Yousaf;Shabana Perween;Syed Sajjad Naqvi;Tarique N.Hasan
作者机构:
Pure Health Laboratory,Mafraq Hospital,Abu Dhabi,United Arab Emirates;Ascencia Business School,College de Paris,France;School of Life Science,Manipal Academy of Higher Education,Dubai,United Arab Emirates
引用格式:
[1]Mati Ur Rehman;Rooh Ullah;Narmeen Arshad;Muhammad Ammad;Qurat Ul Ain;Anam Razzak;Muhammad Yousaf;Shabana Perween;Syed Sajjad Naqvi;Tarique N.Hasan-.Detection of SARS-CoV-2 Eta VOI among international travelers using COVIDSeq-NGS)[J].亚太热带医药杂志(英文版),2022(11):518-521
A类:
COVIDSeq
B类:
Detection,SARS,CoV,Eta,VOI,among,international,travelers,using,NGS,Rationale,has,been,identified,highly,infective,contagious,viral,infection,pandemic,spread,worldwide,affected,more,than,countries,Globally,fast,novel,variants,mostly,attributed,Patient,concerns,We,are,reporting,genomic,evidence,two,Both,were,males,from,Nigeria,aged,years,both,asymptomatic,Diagnosis,nasopharyngeal,swab,samples,positive,by,real,followed,Interventions,Paracetamol,times,daily,days,Outcomes,recovered,completely,within,discharged,after,quarantine,duration,Lessons,This,highlights,variation,For,managing,present,health,crisis,molecular,identification,different,geographical,locations,will,very,helpful
AB值:
0.623876
相似文献
Common mtDNA variations at C5178a and A249d/T6392C/G10310A decrease the risk of severe COVID?19 in a Han Chinese population from Central China
Yi Wu;Xian‑Hui Wang;Xi‑Hua Li;Li‑Yuan Song;Shi‑Long Yu;Zhi‑Cheng Fang;Yu‑Quan Liu;Le‑Yong Yuan;Chun‑Yan Peng;Shen‑Yi Zhang;Wang Cheng;Hong‑Chao Ma;Li‑Feng Wang;Jun‑Ming Tang;Yun‑Fu Wang;Fu‑Yun Ji-Department of Medical Biology,School of Basic Medical Science,Hubei University of Medicine,Shiyan 442000,Hubei,China;Institute of Biomedical Research,Hubei University of Medicine,Shiyan 442000,Hubei,China;Institute of Human Respiratory Disease,Xinqiao Hospital,The Army Medical University(Third Military Medical University),400037 Chongqing,China;Department of Emergency Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Geriatric Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Immunology,School of Basic Medical Sciences,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Laboratory Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China;Hubei Key Laboratory of Embryonic Stem Cell Research,School of Basic Medical Science,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Neurology,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China
The rapid and efficient strategy for SARS-CoV-2 Omicron transmission control: analysis of outbreaks at the city level
Zheng Jin-Xin;Lv Shan;Tian Li-Guang;Guo Zhao-Yu;Zheng Pei-Yong;Chen Yue-Lai;Guan Shi-Yang;Wang Wei-Ming;Zhang Shun-Xian-Department of Nephrology, Ruijin Hospital, Institute of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People’s Republic of China;Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research), NHC Key Laboratory of Parasite and Vector Biology, WHO Collaborating Centre for Tropical Diseases, National Center for International Research On Tropical Diseases, National Institute of Parasitic Diseases, Shanghai 200025, People’s Republic of China;Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, People’s Republic of China;Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei 230032, People’s Republic of China;School of Global Health, Chinese Center for Tropical Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People’s Republic of China;One Health Center, Shanghai Jiao Tong University–The University of Edinburgh, Shanghai 200025, People’s Republic of China
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants
Jia Lu;Qiangling Yin;Rongjuan Pei;Qiu Zhang;Yuanyuan Qu;Yongbing Pan;Lina Sun;Ding Gao;Cuiqin Liang;Jingwen Yang;Wei Wu;Jiandong Li;Zongqiang Cui;Zejun Wang;Xinguo Li;Dexin Li;Shiwen Wang;Kai Duan;Wuxiang Guan;Mifang Lian;Xiaoming Yang-National Engineering Technology Research Center for Combined Vaccines,Wuhan Institute of Biological Products Co.Ltd.,Wuhan,430070,China;State Key Laboratory for Molecular Virology and Genetic Engineering National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing,102206,China;Center for Emerging Infectious Diseases,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China;CDC-WIV Joint Research Center for Emerging Diseases and Biosafety,Wuhan,430071,China;Institution of Infectious Diseases,Shenzhen Bay Laboratory,Shenzhen,518107,China
Comparison of viral propagation and drug response among SARS-CoV-2 VOCs using replicons capable of recapitulating virion assembly and release
Lingqian Tian;Qiuhong Liu;Rongjuan Pei;Yingshan Chen;Chonghui Xu;Jielin Tang;Hao Sun;Kunpeng Liu;Qi Yang;Lei Yang;Leshan Li;Yongli Zhang;Yuan Zhou;Chao Shan;Xue Hu;Xinwen Chen;Yun Wang-State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan,430071,China;University of Chinese Academy of Sciences,Beijing 100049,China;Guangzhou Institutes of Biomedicine and Health,Chinese Academy of Sciences,Guangzhou,510530,China;Department of Gastroenterology,Guangzhou Women and Children's Medical Center,Guangzhou,510623,China;Innovation Center for Pathogen Research,Guangzhou Laboratory,Guangzhou,510320,China
Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum
Yuqi Zhu;Xinyi Yang;Jingna Xun;Jun Liu;Qing Wen;Yixiao Lin;Xiaoting Shen;Jun Chen;Songhua Yuan;Xiaying Zhao;Jing Wang;Hanyu Pan;Jinlong Yang;Zhiming Liang;Yue Liang;Qinru Lin;Huitong Liang;Min Li;Jianping Liu;Yinzhong Shen;Xiaoyan Zhang;Pengfei Wang;Daru Lu;Chunhua Yin;Jianqing Xu;Shibo Jiang;Hongzhou Lu;Huanzhang Zhu-State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology,Ministry of Education,Institute of Genetics,School of Life Sciences,Fudan University,Shanghai,200438,China;Scientific Research Center,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Fubio(Suzhou)Biomedical Technology Co.,Ltd,Suzou,215300,China;Department of Infectious Diseases and Immunology,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences,Fudan University,Shanghai,200032,China;Department of Infectious Diseases and Nursing Research Institution,National Clinical Research Center for Infectious Diseases,The Third People's Hospital of Shenzhen,Shenzhen,518112,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。